Pfizer blazes new research path

Taking a page from the biotech playbook, Pfizer has just inked a three-year, $9.5 million research collaboration pact with the University of California, San Francisco. The money will be used to fund early scientific work into new therapies and devices. Pfizer report

Suggested Articles

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.

At ASH, Dana-Farber researchers presented promising preclinical data on AMG 701, Amgen's long-lasting BiTE for multiple myeloma, but rivals loom.